Akorn signs premix products deal with Bioluz
Akorn in the US has signed a deal with Bioluz SA, a privately held French company, over the production of five premix products.
Akorn in the US has signed a deal with Bioluz SA, a privately held French company, over the production of five premix products.
Premix medications are ready to use intravenous drug products that eliminate compounding steps in the pharmacy or at the point of care. The estimated market size of these five premix products, based on recent IMS data, is approximately $175m.
Akorn will be responsible for the development, regulatory filings, marketing and distribution of the premix product line. Bioluz will exclusively manufacture the products at its intravenous solutions manufacturing facility and Akorn will own the ANDAs.
Akorn currently manufactures sterile specialty pharmaceuticals at manufacturing sites located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.
Bioluz is a contract drug manufacturer focused on premixed drugs in flexible bags. With facilities in Bidart, France, the company seeks partnerships worldwide to provide expertise in injectable drug products in flexible bags.
Financial terms of the agreement were not disclosed.